Immuneering Corp 8K

Immuneering Corporation reported Q1 2026 financial results and business updates, emphasizing advancement of atebimetinib into a pivotal Phase 3 pancreatic cancer trial, positive clinical data, and a cash runway into 2029.

Immuneering Corporation filed a Form 8-K to furnish its first quarter 2026 financial results and provide business updates, highlighting progress of its lead oncology candidate atebimetinib, including new survival data from a Phase 2a trial in first-line metastatic pancreatic cancer to be presented at the 2026 ASCO Annual Meeting, initiation of patient recruitment for the pivotal global Phase 3 MAPKeeper 301 trial in first-line metastatic pancreatic cancer with first dosing expected by mid-2026, robust long-term progression-free survival in a third-line pancreatic cancer patient on atebimetinib monotherapy, and preparations for a Phase 2 lung cancer trial, while reporting a Q1 2026 net loss of $13.5 million on R&D and G&A spending and ending the quarter with $198.6 million in cash, cash equivalents and marketable securities, which management believes will fund operations into 2029.

Filing Facts

CIK

1790340

Ticker

-

Form

8K

Source Type

sec

Accession

0001790340-26-000055

Alert Tier

6